Stay updated on Anetumab Ravtansine Multi-indication Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Multi-indication Clinical Trial page.

Latest updates to the Anetumab Ravtansine Multi-indication Clinical Trial page
- CheckyesterdayChange DetectedClinicalTrials.gov’s page version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a site release rather than a change to the trial content.SummaryDifference0.0%

- Check8 days agoChange DetectedThe page revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check51 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3. No user-facing content or study details appear to be affected.SummaryDifference0.0%

- Check72 days agoChange DetectedMinor site-wide footer and label edits include the addition of a revision note (Revision: v3.4.2) and the removal of Bayer-related links/labels such as 'Click here to find results for studies related to Bayer products', 'Bayer', and 'Helpful Links Provided by'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedMinor revision from v3.4.0 to v3.4.1; no substantive changes to the study content, eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Anetumab Ravtansine Multi-indication Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Multi-indication Clinical Trial page.